| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2024 | 845 | 1.790 |
Why?
|
| Renal Dialysis | 16 | 2021 | 947 | 1.750 |
Why?
|
| Peritoneal Dialysis | 11 | 2021 | 137 | 1.750 |
Why?
|
| Antimicrobial Cationic Peptides | 6 | 2014 | 39 | 1.460 |
Why?
|
| Kidney Failure, Chronic | 11 | 2021 | 950 | 1.340 |
Why?
|
| Hepcidins | 7 | 2016 | 27 | 1.040 |
Why?
|
| Catheters, Indwelling | 5 | 2017 | 157 | 1.030 |
Why?
|
| Iron | 6 | 2022 | 302 | 0.940 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2023 | 33 | 0.840 |
Why?
|
| Peritonitis | 4 | 2021 | 76 | 0.830 |
Why?
|
| Nephrocalcinosis | 1 | 2023 | 8 | 0.800 |
Why?
|
| Nephrolithiasis | 1 | 2023 | 15 | 0.790 |
Why?
|
| Kidney Diseases | 5 | 2022 | 489 | 0.780 |
Why?
|
| Kidney Calculi | 1 | 2023 | 49 | 0.760 |
Why?
|
| Genetic Testing | 3 | 2023 | 1099 | 0.730 |
Why?
|
| Hematinics | 5 | 2018 | 59 | 0.690 |
Why?
|
| Proteinuria | 3 | 2024 | 110 | 0.690 |
Why?
|
| Hypertension | 2 | 2020 | 1396 | 0.680 |
Why?
|
| Nephrotic Syndrome | 4 | 2023 | 51 | 0.640 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 50 | 0.630 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2019 | 5 | 0.630 |
Why?
|
| Blood Component Removal | 1 | 2019 | 35 | 0.610 |
Why?
|
| Catheter-Related Infections | 3 | 2021 | 136 | 0.600 |
Why?
|
| Kidney Transplantation | 4 | 2023 | 570 | 0.600 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 133 | 0.590 |
Why?
|
| Plasmapheresis | 2 | 2023 | 33 | 0.580 |
Why?
|
| Erythropoietin | 2 | 2016 | 107 | 0.580 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 116 | 0.560 |
Why?
|
| Ferrosoferric Oxide | 2 | 2016 | 28 | 0.550 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 946 | 0.550 |
Why?
|
| Pediatricians | 1 | 2018 | 73 | 0.550 |
Why?
|
| Fanconi Syndrome | 1 | 2017 | 9 | 0.540 |
Why?
|
| Iron Chelating Agents | 1 | 2017 | 15 | 0.540 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2016 | 165 | 0.530 |
Why?
|
| Benzoates | 1 | 2017 | 22 | 0.530 |
Why?
|
| Kidney Tubules | 1 | 2016 | 74 | 0.510 |
Why?
|
| Blood Pressure | 2 | 2020 | 1400 | 0.500 |
Why?
|
| Triazoles | 1 | 2017 | 146 | 0.500 |
Why?
|
| Renal Replacement Therapy | 2 | 2015 | 158 | 0.480 |
Why?
|
| Guideline Adherence | 1 | 2018 | 393 | 0.480 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 670 | 0.480 |
Why?
|
| Anemia | 2 | 2016 | 350 | 0.460 |
Why?
|
| Fibroblast Growth Factors | 3 | 2022 | 166 | 0.440 |
Why?
|
| Ultrafiltration | 1 | 2014 | 12 | 0.440 |
Why?
|
| Contrast Media | 2 | 2016 | 507 | 0.430 |
Why?
|
| Premature Birth | 1 | 2018 | 418 | 0.430 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 256 | 0.430 |
Why?
|
| Biomarkers | 7 | 2013 | 3402 | 0.420 |
Why?
|
| Child | 27 | 2024 | 25765 | 0.420 |
Why?
|
| Hyperammonemia | 1 | 2014 | 62 | 0.410 |
Why?
|
| Urology | 1 | 2014 | 87 | 0.400 |
Why?
|
| Humans | 52 | 2024 | 132013 | 0.390 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2024 | 137 | 0.390 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2018 | 141 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 767 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 222 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1300 | 0.370 |
Why?
|
| Ramipril | 1 | 2012 | 4 | 0.370 |
Why?
|
| Potassium Channels | 4 | 2001 | 160 | 0.360 |
Why?
|
| Tetrazoles | 1 | 2012 | 69 | 0.360 |
Why?
|
| Valine | 1 | 2012 | 111 | 0.360 |
Why?
|
| Young Adult | 15 | 2023 | 9952 | 0.350 |
Why?
|
| Phosphorus | 2 | 2013 | 61 | 0.340 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2001 | 39 | 0.340 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 826 | 0.330 |
Why?
|
| Disease Management | 1 | 2014 | 562 | 0.330 |
Why?
|
| Child, Preschool | 17 | 2019 | 14736 | 0.330 |
Why?
|
| Male | 33 | 2021 | 64914 | 0.320 |
Why?
|
| Thiosulfates | 1 | 2009 | 7 | 0.320 |
Why?
|
| Radioimmunoassay | 1 | 2009 | 99 | 0.320 |
Why?
|
| Uremia | 1 | 2009 | 37 | 0.320 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2009 | 21 | 0.310 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2009 | 34 | 0.310 |
Why?
|
| Adolescent | 20 | 2020 | 20544 | 0.310 |
Why?
|
| Sodium Bicarbonate | 1 | 2009 | 56 | 0.310 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 1439 | 0.300 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 119 | 0.300 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 241 | 0.290 |
Why?
|
| Drug Resistance | 1 | 2009 | 252 | 0.290 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 2311 | 0.280 |
Why?
|
| Calcinosis | 1 | 2009 | 191 | 0.280 |
Why?
|
| Infant | 11 | 2019 | 13050 | 0.270 |
Why?
|
| Inflammation | 2 | 2012 | 1519 | 0.270 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 96 | 0.270 |
Why?
|
| Retrospective Studies | 9 | 2023 | 17374 | 0.270 |
Why?
|
| Antioxidants | 1 | 2009 | 333 | 0.260 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 139 | 0.260 |
Why?
|
| Female | 30 | 2021 | 70643 | 0.260 |
Why?
|
| Vitamin D | 4 | 2022 | 183 | 0.250 |
Why?
|
| Ferritins | 4 | 2013 | 109 | 0.250 |
Why?
|
| Dialysis Solutions | 2 | 2018 | 17 | 0.230 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 573 | 0.220 |
Why?
|
| Naphthyridines | 1 | 2024 | 10 | 0.220 |
Why?
|
| Adult | 14 | 2024 | 31563 | 0.210 |
Why?
|
| Infant, Newborn | 5 | 2018 | 8542 | 0.210 |
Why?
|
| Hospitals | 2 | 2023 | 438 | 0.210 |
Why?
|
| Hemoglobins | 3 | 2018 | 322 | 0.200 |
Why?
|
| Diabetic Nephropathies | 1 | 2024 | 115 | 0.200 |
Why?
|
| Bicarbonates | 1 | 2023 | 100 | 0.200 |
Why?
|
| C-Reactive Protein | 3 | 2010 | 464 | 0.190 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 79 | 0.190 |
Why?
|
| Recurrence | 3 | 2023 | 1453 | 0.180 |
Why?
|
| Erythropoiesis | 3 | 2012 | 37 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1294 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 74 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 276 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2023 | 6568 | 0.170 |
Why?
|
| Rickets, Hypophosphatemic | 1 | 2020 | 1 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2020 | 3 | 0.170 |
Why?
|
| Time Factors | 4 | 2018 | 6441 | 0.170 |
Why?
|
| Creatinine | 2 | 2019 | 412 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 5 | 0.170 |
Why?
|
| Hypercalciuria | 1 | 2020 | 8 | 0.170 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 56 | 0.160 |
Why?
|
| Potassium | 2 | 2000 | 275 | 0.160 |
Why?
|
| Cerebral Arteries | 1 | 2000 | 83 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3760 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5409 | 0.160 |
Why?
|
| Pulse Therapy, Drug | 1 | 2019 | 9 | 0.160 |
Why?
|
| Vasodilation | 1 | 2000 | 181 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 74 | 0.150 |
Why?
|
| Risk Factors | 7 | 2019 | 10931 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2021 | 245 | 0.150 |
Why?
|
| Kidney Glomerulus | 1 | 2019 | 81 | 0.150 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 76 | 0.150 |
Why?
|
| Nephrology | 1 | 2021 | 158 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 238 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2018 | 74 | 0.150 |
Why?
|
| Diphosphates | 1 | 2018 | 8 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 73 | 0.150 |
Why?
|
| Remission Induction | 1 | 2019 | 306 | 0.150 |
Why?
|
| Allografts | 1 | 2019 | 195 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2019 | 12987 | 0.140 |
Why?
|
| Parathyroid Hormone | 3 | 2013 | 83 | 0.140 |
Why?
|
| Fibric Acids | 1 | 2017 | 7 | 0.140 |
Why?
|
| Minerals | 2 | 2022 | 58 | 0.140 |
Why?
|
| Half-Life | 1 | 2017 | 160 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2019 | 294 | 0.130 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2018 | 176 | 0.130 |
Why?
|
| Blood Urea Nitrogen | 1 | 2016 | 71 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 267 | 0.130 |
Why?
|
| Birth Weight | 1 | 2018 | 350 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2011 | 1234 | 0.130 |
Why?
|
| Survival Rate | 3 | 2017 | 2188 | 0.130 |
Why?
|
| Serum Amyloid A Protein | 1 | 2016 | 44 | 0.130 |
Why?
|
| Drug Overdose | 1 | 2017 | 74 | 0.130 |
Why?
|
| Phosphates | 2 | 2022 | 114 | 0.120 |
Why?
|
| Myocardium | 1 | 2001 | 906 | 0.120 |
Why?
|
| Overweight | 1 | 2019 | 383 | 0.120 |
Why?
|
| Adenine | 1 | 2016 | 120 | 0.120 |
Why?
|
| Age Factors | 3 | 2018 | 2911 | 0.120 |
Why?
|
| Mice, Knockout | 3 | 2016 | 3865 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 732 | 0.120 |
Why?
|
| Nephrosis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2018 | 819 | 0.120 |
Why?
|
| Infant, Premature | 2 | 2018 | 843 | 0.120 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2012 | 33 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 239 | 0.110 |
Why?
|
| Hernia, Hiatal | 1 | 2015 | 60 | 0.110 |
Why?
|
| Macrophages, Peritoneal | 1 | 2014 | 39 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2017 | 241 | 0.110 |
Why?
|
| Calcium | 4 | 2013 | 1079 | 0.110 |
Why?
|
| Prognosis | 4 | 2018 | 5008 | 0.110 |
Why?
|
| Gestational Age | 1 | 2018 | 1226 | 0.110 |
Why?
|
| Gadolinium | 1 | 2014 | 116 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1411 | 0.100 |
Why?
|
| Hyperphosphatemia | 1 | 2013 | 19 | 0.100 |
Why?
|
| Hypercalcemia | 1 | 2013 | 42 | 0.100 |
Why?
|
| Hernia, Abdominal | 1 | 2013 | 18 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2013 | 26 | 0.100 |
Why?
|
| Ergocalciferols | 1 | 2012 | 5 | 0.100 |
Why?
|
| Models, Structural | 1 | 2012 | 47 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2015 | 606 | 0.100 |
Why?
|
| Disease Progression | 1 | 2019 | 2226 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2015 | 309 | 0.100 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2014 | 120 | 0.100 |
Why?
|
| Middle Aged | 10 | 2020 | 28968 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2019 | 801 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2013 | 136 | 0.090 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 58 | 0.090 |
Why?
|
| Microcephaly | 1 | 2015 | 351 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 56 | 0.090 |
Why?
|
| Valsartan | 1 | 2012 | 28 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 7105 | 0.090 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2011 | 13 | 0.090 |
Why?
|
| Length of Stay | 1 | 2017 | 1380 | 0.090 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 57 | 0.090 |
Why?
|
| Aged | 7 | 2020 | 21406 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 2442 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 113 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 742 | 0.080 |
Why?
|
| Phosphorus, Dietary | 1 | 2010 | 4 | 0.080 |
Why?
|
| Calcium Phosphates | 1 | 2010 | 10 | 0.080 |
Why?
|
| Malnutrition | 1 | 2012 | 161 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2010 | 38 | 0.080 |
Why?
|
| Hemodialysis Solutions | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hypocalcemia | 1 | 2010 | 38 | 0.080 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2011 | 156 | 0.080 |
Why?
|
| Sevelamer | 1 | 2009 | 11 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2009 | 46 | 0.080 |
Why?
|
| Diet | 1 | 2016 | 1125 | 0.080 |
Why?
|
| Polyamines | 1 | 2009 | 31 | 0.080 |
Why?
|
| Proteins | 1 | 2015 | 1036 | 0.080 |
Why?
|
| Safety | 1 | 2010 | 216 | 0.080 |
Why?
|
| Iron-Binding Proteins | 1 | 2009 | 33 | 0.080 |
Why?
|
| Global Health | 1 | 2014 | 643 | 0.080 |
Why?
|
| Animals | 7 | 2016 | 34804 | 0.080 |
Why?
|
| Mice | 4 | 2016 | 18478 | 0.070 |
Why?
|
| Child Development | 1 | 2011 | 271 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 364 | 0.070 |
Why?
|
| Kinetics | 1 | 2010 | 1130 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 1246 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 679 | 0.070 |
Why?
|
| United States | 1 | 2023 | 11655 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2009 | 435 | 0.070 |
Why?
|
| Animals, Newborn | 2 | 2001 | 1033 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 4757 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 450 | 0.060 |
Why?
|
| Mollusca | 2 | 1999 | 11 | 0.060 |
Why?
|
| Incidence | 1 | 2014 | 3375 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4684 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 3008 | 0.060 |
Why?
|
| Reference Values | 2 | 2011 | 703 | 0.060 |
Why?
|
| Mutation | 2 | 2020 | 6226 | 0.060 |
Why?
|
| Echocardiography | 1 | 2011 | 1124 | 0.060 |
Why?
|
| Asia | 2 | 2019 | 126 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 485 | 0.060 |
Why?
|
| Europe | 2 | 2019 | 372 | 0.060 |
Why?
|
| Cathelicidins | 2 | 2014 | 13 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1457 | 0.050 |
Why?
|
| Sclerosis | 1 | 2023 | 33 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2024 | 83 | 0.050 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 45 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 1999 | 317 | 0.050 |
Why?
|
| Electric Conductivity | 2 | 2001 | 86 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3182 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 309 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 102 | 0.050 |
Why?
|
| Retina | 2 | 1999 | 490 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2022 | 22 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 650 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 112 | 0.050 |
Why?
|
| Ferric Compounds | 1 | 2022 | 41 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 308 | 0.040 |
Why?
|
| Phenotype | 2 | 2001 | 4526 | 0.040 |
Why?
|
| Counselors | 1 | 2021 | 24 | 0.040 |
Why?
|
| Reaction Time | 1 | 2001 | 167 | 0.040 |
Why?
|
| Colforsin | 1 | 2000 | 51 | 0.040 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2000 | 33 | 0.040 |
Why?
|
| Basilar Artery | 1 | 2000 | 26 | 0.040 |
Why?
|
| Action Potentials | 2 | 2001 | 491 | 0.040 |
Why?
|
| Forms and Records Control | 1 | 2019 | 11 | 0.040 |
Why?
|
| Information Services | 1 | 2019 | 22 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 218 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 52 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 243 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 321 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 862 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 98 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 439 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 1999 | 62 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2013 | 5166 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 2655 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1579 | 0.040 |
Why?
|
| Cleft Palate | 1 | 2000 | 154 | 0.040 |
Why?
|
| Quality of Life | 1 | 2008 | 2157 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 793 | 0.040 |
Why?
|
| Cholesterol, VLDL | 1 | 2017 | 18 | 0.030 |
Why?
|
| Heterozygote | 1 | 2020 | 713 | 0.030 |
Why?
|
| Lipoprotein Lipase | 1 | 2017 | 61 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 600 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.030 |
Why?
|
| RNA | 1 | 2001 | 552 | 0.030 |
Why?
|
| Niacin | 1 | 2017 | 59 | 0.030 |
Why?
|
| Lipase | 1 | 2017 | 97 | 0.030 |
Why?
|
| Ezetimibe | 1 | 2017 | 94 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2017 | 81 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 3993 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 748 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2001 | 782 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2017 | 186 | 0.030 |
Why?
|
| Pedigree | 1 | 2020 | 1719 | 0.030 |
Why?
|
| Neurons | 2 | 1999 | 2002 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2017 | 189 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 398 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1284 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2001 | 994 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1443 | 0.030 |
Why?
|
| Tubulin | 1 | 2015 | 73 | 0.030 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2015 | 32 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 777 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2015 | 52 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 617 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 558 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1500 | 0.030 |
Why?
|
| Ileum | 1 | 2015 | 130 | 0.030 |
Why?
|
| Gastroschisis | 1 | 2015 | 57 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 185 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2013 | 124 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 94 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 699 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 415 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 547 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 152 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 3043 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2013 | 100 | 0.020 |
Why?
|
| Kidney | 1 | 2019 | 1329 | 0.020 |
Why?
|
| Omentum | 1 | 2013 | 47 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 97 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 18 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1718 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 61 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2013 | 92 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2012 | 51 | 0.020 |
Why?
|
| Meningitis | 1 | 2012 | 100 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 138 | 0.020 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2015 | 248 | 0.020 |
Why?
|
| South America | 1 | 2011 | 42 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 163 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 56 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 241 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 257 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 523 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2015 | 512 | 0.020 |
Why?
|
| Mortality | 1 | 2012 | 263 | 0.020 |
Why?
|
| North America | 1 | 2011 | 265 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1993 | 472 | 0.020 |
Why?
|
| Critical Illness | 1 | 2015 | 618 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2013 | 252 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 204 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1011 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 852 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1441 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1671 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 1572 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2013 | 523 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 485 | 0.020 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 1999 | 6 | 0.010 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 11 | 0.010 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 29 | 0.010 |
Why?
|
| Metals | 1 | 1999 | 66 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 123 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 1999 | 294 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1999 | 303 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 295 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 742 | 0.010 |
Why?
|
| Axons | 1 | 1999 | 390 | 0.010 |
Why?
|